+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019

  • ID: 4769203
  • Drug Pipelines
  • 80 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Celularity Inc
  • Commence Bio Inc
  • Grunenthal GmbH
  • Medifron DBT Co Ltd
  • MORE
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

"Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics."

Report Highlights

This latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 3 and 9 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Celularity Inc
  • Commence Bio Inc
  • Grunenthal GmbH
  • Medifron DBT Co Ltd
  • MORE
Introduction

Diabetic Peripheral Neuropathy - Overview

Diabetic Peripheral Neuropathy - Therapeutics Development

Diabetic Peripheral Neuropathy - Therapeutics Assessment

Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development

Diabetic Peripheral Neuropathy - Drug Profiles

Diabetic Peripheral Neuropathy - Dormant Projects

Diabetic Peripheral Neuropathy - Discontinued Products

Diabetic Peripheral Neuropathy - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Applied Therapeutics Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Celularity Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Neuralstem Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H1 2019

Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H1 2019

Diabetic Peripheral Neuropathy - Dormant Projects, H1 2019

Diabetic Peripheral Neuropathy - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Celularity Inc
  • Commence Bio Inc
  • Grunenthal GmbH
  • Immune Pharmaceuticals Inc
  • Medifron DBT Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Neuralstem Inc
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • Sphaera Pharma Pte Ltd
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4769203
Adroll
adroll